Yuhan Corp. has secured an 84.9 billion won ($64.5 million) contract to supply hepatitis C treatment APIs to Gilead Sciences, representing 4.11% of its annual sales, with deliveries set from May 2026 to May 2027.
#YonhapInfomax #YuhanCorp #GileadSciences #HepatitisCTreatment #APISupply #849BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=78889

Yuhan Corp. has secured an 84.3 billion won ($63.5 million) API supply contract with Gilead Sciences for HIV treatments, representing 4.08% of its annual sales.
#YonhapInfomax #YuhanCorp #GileadSciences #APISupply #HIVTreatment #843BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77789

Yuhan Corporation secures 88.8 billion won contract with Gilead Sciences for additional supply of HIV treatment API, expanding on previous 107.7 billion won deal
#YonhapInfomax #YuhanCorporation #GileadSciences #HIVTreatment #APISupply #PharmaceuticalContract #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64398